ArticleJournal of research in medical sciences : the official journal of Isfahan University of Medical Sciences2019
Association between Ki-67 expression and clinicopathological features in prognosis of breast cancer: A retrospective cohort study.
Article in Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- Preoperative systemic inflammatory markers (SII, PLR, MRR) as potential indicators of axillary lymph node metastasis in early-stage breast cancer.Discover oncology · 2026Article
- Preoperative prediction of breast cancer Ki-67 status via multimodal ultrasound-clinical nomogram: a single-center study.Translational cancer research · 2025Article
- Differences in Clinical, Epidemiological, and Pathological Features of Breast Cancer in the Saudi Population: An Analytical Cross-Sectional Single Institution Study.Healthcare (Basel, Switzerland) · 2025Article
- Characterization of intrinsic subtypes of breast cancer and their relationship with staging: an observational study.Frontiers in medicine · 2025Article
- A comprehensive analysis of the prognostic value, expression characteristics and immune correlation of MKI67 in cancers.Frontiers in immunology · 2025Article
- Expression of Ki-67 in Invasive Breast Carcinoma and Its Correlation With Different Clinicopathological Features.Cureus · 2024Article
- Oncotype DX in Breast Cancer Management: Insights and Outcomes From the United Arab Emirates.Cureus · 2024Article
- Peripheral Neutrophil to Lymphocyte Ratio (NLR), a cogent clinical adjunct for Ki-67 in breast cancer.Journal of the Egyptian National Cancer Institute · 2023Observational
- Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study.Breast cancer research : BCR · 2022Article
- XGboost Prediction Model Based on 3.0T Diffusion Kurtosis Imaging Improves the Diagnostic Accuracy of MRI BiRADS 4 Masses.Frontiers in oncology · 2022Article
- Rotter's Lymph Nodes-Do We Really Need to Remove During Axillary Clearance?Indian journal of surgical oncology · 2021Article
- Article
- Correlation between apparent diffusion coefficient and pathological characteristics of patients with invasive breast cancer.Annals of translational medicine · 2021Article
- Immunohistochemical expression of substance P in breast cancer and its association with prognostic parameters and Ki-67 index.PloS one · 2021Article
- Immunohistochemical Expression of IRE1 and PERK in Breast Cancer: Associations With Clinicopathological Characteristics and Survival Outcomes.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is the most common diagnosed female cancer. Breast cancer is also the leading cause of cancer death in females accounting for 13.7% of female cancer-related mortality globally. Variable known prognostic factors such as histological tumor type, tumor size, nodal status, grade, age, and estrogen receptor (ER) status and the proliferation marker - Ki-67 influence the type of treatment decision. The purpose of this present study is to investigate the association between Ki-67 expression with several clinicopathological variables and patients' outcome. MATERIALS AND
methodsThis is a retrospective cohort study from September 2008 to March 2017; 165 newly diagnosed breast cancer patients were enrolled in the study. Ki67 levels were measured using immunohistochemistry and compared with clinicopathological variables. The relation of Ki67 expression with disease-free survival (DFS) and overall survival (OS) was also analyzed.
resultsThe result of this study revealed that age, tumor size, menopausal status, and human epidermal growth factor receptor 2 (HER2) status had no effect on the patients' outcome. Patients with ER-positive, progesterone receptor (PR)-positive, and HER2-negative tumors expressed a higher rate of Ki-67 (>10%) than patients with ER-negative, PR-negative, and HER2-positive tumors, respectively. However, we found that Ki-67 levels were not significantly increased statistically with ER, PR, and HER2 statuses. There was a statistically significant correlation between Ki-67 expression and with higher stages of the disease. Multivariate analysis showed that Ki-67 expression could not to be an independent prognostic factor for 5-year OS and DFS. Furthermore, p53 status was only prognostic factor for 5-year OS whereas higher stages of disease and p53 status were prognostic factors for 5-year DFS.
conclusionKi67 could not be an independent variable for prediction of breast cancer outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.